Last quarter (Q4 2023), Inozyme Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Inozyme Pharma's net income was $-21.54M. See Inozyme Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 75.64M	$ 75.64M	$ 68.67M	$ 56.65M	$ 57.04M	$ 20.81M
Operating Income	$ -75.64M	$ -75.64M	$ -68.67M	$ -56.65M	$ -57.04M	$ -20.81M
Net Non Operating Interest Income Expense	$ 4.50M	$ 4.50M	$ 1.93M	$ 211.00K	$ 370.00K	$ 1.11M
Other Income Expense	$ 28.00K	$ 28.00K	$ 319.00K	$ 189.00K	$ 247.00K	$ -24.00K
Pretax Income	$ -71.17M	$ -71.17M	$ -67.06M	$ -56.62M	$ -56.42M	$ -19.72M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -71.17M	$ -71.17M	$ -67.06M	$ -56.62M	$ -56.42M	$ -19.72M
Basic EPS	$ -1.39	$ -1.37	$ -1.78	$ -2.40	$ -5.11	$ -1.30
Diluted EPS	$ -1.39	$ -1.37	$ -1.78	$ -2.40	$ -5.11	$ -1.30
Basic Average Shares	$ 207.36M	$ 51.84M	$ 37.76M	$ 23.56M	$ 11.04M	$ 15.14M
Diluted Average Shares	$ 207.36M	$ 51.84M	$ 37.76M	$ 23.56M	$ 11.04M	$ 15.14M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 75.64M	$ 75.64M	$ 68.67M	$ 56.65M	$ 57.04M	$ 20.81M
Net Income From Continuing And Discontinued Operation	$ -71.17M	$ -71.17M	$ -67.06M	$ -56.62M	$ -56.42M	$ -19.72M
Normalized Income	$ -30.16M	$ -56.22M	$ -52.98M	-	$ -56.42M	$ -19.72M
Interest Expense	-	-	-	-	-	-
EBIT	$ -67.84M	$ -67.84M	$ -67.06M	$ -56.62M	$ -57.04M	$ -20.81M
EBITDA	$ -71.81M	$ -71.81M	$ -67.89M	$ -55.78M	$ -56.82M	$ -20.72M

Currency in USD

Inozyme Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing